Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children

Catherine O Falade, Oluwatoyin O Ogunkunle, Hannah O Dada-Adegbola, Adegoke G Falade, Patricia Ibarra de Palacios, Philip Hunt, Mailis Virtanen, Ayoade M Oduola, Lateef A Salako, Catherine O Falade, Oluwatoyin O Ogunkunle, Hannah O Dada-Adegbola, Adegoke G Falade, Patricia Ibarra de Palacios, Philip Hunt, Mailis Virtanen, Ayoade M Oduola, Lateef A Salako

Abstract

Background: The six-dose regimen of artemether-lumefantrine (AL) is now considered the gold standard for the treatment of uncomplicated Plasmodium falciparum malaria. There are few reports evaluating co-artemether in very young Nigerian infants and children. Results of the evaluation of the six-dose regimen in very young infants and children in Nigeria are presented in this report.

Methods: As part of a larger African study, this open label, non-comparative trial, assessed the efficacy and safety of six-dose regimen of AL tablets in 103 Nigerian infants and children weighing between five and 25 kg suffering from acute uncomplicated malaria. Treatment was administered under supervision over three days with children as in-patients. 12-lead ECG tracings were taken pre-treatment and at day 3.

Results: Ninety-three infants and children completed the study as stipulated by the protocol. Mean fever and parasite clearance times for the intent to treat population (ITT) were 24.9 h +/- (1.28) and 26 h +/- (4.14) and the corresponding figures for the per-protocol population (PP) were 19.24 h +/- 13.9 and 25.62 h +/- 11.25 respectively. Day 14 cure rates for the ITT and PP were 95.1% and 100% respectively while day 28 cure rates were 91.3% and 95.7% respectively. The overall PCR corrected day 28 cure rate was 95.1% for the ITT. The six-dose regimen of AL was well tolerated with no drug-related serious adverse events. Although six patients recorded a QTc prolongation of > 60 ms on D3 over D0 recording, no patient recorded a QTc interval > 500 ms.

Conclusion: The six-dose regimen of AL tablets is safe and effective for the treatment of acute uncomplicated malaria in Nigerian infants and children weighing between five and 25 kg.

Trial registration: NCT00709969.

References

    1. Zucker JR, Ruebush , TK II, Obonyo C, Otieno J, Campbell CC. The mortality consequences of chloroquine use in Africa: Experience in Siaya, Western Kenya. Am J Trop Med Hyg. 2003;68:386–390.
    1. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12–17.
    1. Jiao X, Liu GY, Shao CO, Zhao X, Galliman I, Royce C. Phase II trial in China of a new rapidly acting and effective oral antimalarial CGP 56697 for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health. 1999;28:476–481.
    1. Kshirsagar NA, Gogtay NJ, Moorthy NS, Gard MR, Dalvi SS, Chogle AR, Sorabjee JS, Marathe SN, Tilve GH, Bhatt AD, Sane SP, Mull R, Gathmann I. A randomized, double blind, parallel-group, comparative safety and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am J Trop Med Hyg. 2000;62:402–408.
    1. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug resistant falciparum malaria. Antimicrob Agents Chemother. 1998;42:135–139.
    1. van Vugt M, Nilairataria P, Gemperli B, Fathman I, Phaipun L, Broockman PA, Luxemburger C, White NJ, Nosten F, Looareesuwan S. Efficacy of six-doses of artemether-lumefantrine (benflumetol) in multi drug resistant Plasmodium falciparum malaria. Am J Trop Med Hyg. 1999;60:936–942.
    1. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon I, Mull R, Bakshi R. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistance Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 2001;64:247–256.
    1. Makanga M, Premji Z, Falade C, Karbwang K, Mueller EA, Andriano K, Hunt P, Ibarra de Palacios P. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg. 2006;74:991–998.
    1. Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, Heifer MH, Schuster BG. Fatal neurotoxicity of artemether and arteether. Am J Trop Med Hyg. 1994;51:251–259.
    1. Kamchonwongpaisan S, McKeever P, Hossler O, Ziffer H, Meshinick SR. Artemisinin neurotoxicity: Neuropathology in rats and mechanistic studies in-vitro. Am J Trop Med Hyg. 1996;56:7–12.
    1. Castot A, Rappaport P, LeCoz P. Prolonged Q-Tc interval with halofantrine. Lancet. 1993;341:1541. doi: 10.1016/0140-6736(93)90685-A.
    1. Falade C, Makanga M, Premji Z, Ortmann C-E, Stockmeyer M, Ibarra de Palacios P. Efficacy and safety of six dose artemether-lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children treatment of acute uncomplicated malaria. Trans R Soc Trop Med Hyg. 2005;99:459–467. doi: 10.1016/j.trstmh.2004.09.013.
    1. Snounou G, Beck H. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today. 1998;14:462–467. doi: 10.1016/S0169-4758(98)01340-4.
    1. Abdu-Aguye I, Gebi UI, Wuyat A, Agbo M. An open-label uncontrolled trial confirming efficacy and safety of the 4-dose regimen of Coartem® in the treatment of acute Plasmodium falciparum malaria in patients aged > 2 years in Zaria Nigeria. Report of a Clinical Trial, Novartis Pharma AG Nigeria study Report; 2000.
    1. Eke F, Akhidue V, Ukiwo UE, Akosubo IJ, Izuora P, Akpan PU, Ufford M, Ugwumba F, Dennis A. Report of an open-label uncontrolled trial confirming efficacy and safety of a 4-dose regimen of Coartem® [artemether-lumefantrine (benflumetol)] in the treatment of acute Plasmodium falciparum malaria in children in Port Harcourt. Novartis Pharma AG Nigeria study Report; 2000.
    1. Ezedinachi EN, Ekanem-Ephraim E, Ndifon N, Amaechi V, Alaribe AA, Bam AB. An open-label uncontrolled trial confirming efficacy and safety of the 4-dose regimen of Coartem® in the treatment of acute Plasmodium falciparum malaria in patients aged > 2 years in Calabar Nigeria. Report of a Clinical Trial Novartis Pharma AG Nigeria study Report; 2000.
    1. Salako LA, Adewole TA, Afolabi BM, Mafe AG. An open-label uncontrolled trial confirming efficacy and safety of the 4-dose regimen of Coartem® in the treatment of acute Plasmodium falciparum malaria in patients aged > 2 years in Lagos Nigeria. Report of a Clinical Trial. Novartis Pharma AG Nigeria study Report; 2000.
    1. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ. No evidence of cardiotoxicity during treatment with artemether-lumefantrine. Am J Trop Med Hyg. 1999;61:964–967.
    1. Bindschedler M, Lefèvre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am J Trop Med Hyg. 2002;66:293–298.
    1. Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, Beck H, Tanner M, Royce C. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1–5 years. Trop Med Int Health. 1998;3:498–504. doi: 10.1046/j.1365-3156.1998.00250.x.
    1. Seidlein LV, Borjarg K, Jones P, Jaffar S, Pinder M, Grathman I, Royce C, McAdams K, Greenwood B. A randomized controlled trial of artemether-benflumetol, a new antimalarial and sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in African children. Am J Trop Med Hyg. 1998;58:638–644.
    1. Meremikwu M, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, Nwachuckwu C, Ordu D, Ezedinachi E. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated malaria in Nigeria: randomized controlled trial. Malar J. 2006;5:43. doi: 10.1186/1475-2875-5-43.
    1. Ashley EA, Stepniewska K, Lindegardh N, Anneberg A, Khan AM, Brockman AI, Singhasivanon P, White NJ, Nosten F. How much fat is necessary to optimize lumefantrine oral bioavailability. Trop Med Int Health. 2007;12:195–198.
    1. FMOH . National Treatment guidelines for the treatment of malaria in Nigeria. Federal Ministry of Health; 2005.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner